Search, analyze & compare

My selected companies

Adjust valuation method
WatchlistNameTickerP/EP/SP/BEV/EbitdaROEROICRSISMA200DCFVolumeClosing price
-
Caribou Biosciences, Inc.CRBU-1.445.020.480.41-42.57%-10.14%41.48$1.95$4.5315,786$1.84

Detail of Caribou Biosciences, Inc.

 
CEO
Dr. Rachel E. Haurwitz Ph.D.
Employees
158
Industry
Biotechnology
Sector
Healthcare
Market cap
$166M

Company details

Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma. The company also develops CB-011, an allogeneic anti-BCMA CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory multiple myeloma; and CB-012, an allogeneic anti-CD371 CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory acute myeloid leukemia. Caribou Biosciences, Inc. was incorporated in 2011 and is headquartered in Berkeley, California.

Revenue
Revenue (Rev)
$33.11M
Caribou Biosciences, Inc.
CRBU • XNGS • US
$1.84
-2.68 (-59.16%)
Stock vs Industry average
  • Industry average

Negative values are hidden from the graph.
Trailing annual dividend rate
$0.00
Payout ratio
0.00%
EPS
-$1.28
Margin profit
0.00%
52 week low
$1.56
52 week high
$8.26
50-day simple moving average
$1.88
200-day simple moving average
$1.95
Percent held by insiders
10.05%
Percent held by institutions
62.76%
Dividend yield
0.00%

Change of shares

Cash vs Debt

Insider Trading

Comparison of selected companies

 
%
Price change
CRBU -58.14%
eps change
CRBU 0.00%